Table 2 Demographic data, lung function and therapy of patients.

0380

male

69

0.74

1.58

0.47

IV

ex

97.6

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

25 mg glucocorticoid/day

0436

male

39

1.57

3.72

0.42

II

ex

85.7

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

35 mg glucocorticoid/day, theophyllin

0438

male

59

0.8

3.12

0.26

IV

ex

95.3

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

25 mg glucocorticoid/day, theophyllin

0449

male

67

0.98

2.51

0.39

III

ex

95.6

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

40 mg glucocorticoid/day, theophyllin

0462

female

62

1.03

2.26

0.46

II

ex

84

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

5 mg glucocorticoid/day, theophyllin

0463

male

64

1.48

3.07

0.48

III

ex

88.1

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

15 mg glucocorticoid/day, theophyllin

0487

male

73

0.96

2.33

0.41

III

ex

81.2

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

15 mg glucocorticoid/day

0565

male

81

1.15

2.92

0.39

II

ex

84.9

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

30 mg glucocorticoid/day

0834

male

72

0.96

2.33

0.41

III

ex

68

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist

1315

male

76

1.1

3.92

0.28

III

ex

84

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist

30 mg glucocorticoid/day

1336

male

71

0.86

3.15

0.27

III

ex

80.6

short acting β₂ agonist, anti-cholinergic, long acting β₂ agonist, glucocorticoids

10 mg glucocorticoid/day